ArticleInfection and drug resistance2025
Clinical Characteristics and Independent Risk Factors for Multidrug-Resistant
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Risk factors, resistance profiles, and clinical outcomes ofFrontiers in cellular and infection microbiology · 2026Article
- Synergistic Interactions Between Natural Phenolic Compounds and Antibiotics Against Multidrug-ResistantMicroorganisms · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to analyze the clinical characteristics and risk factors of multidrug-resistant Patients and Methods: A retrospective analysis of 240 adult patients with KP-BSI (2019-2023) was conducted. Clinical data were analyzed using multivariable logistic regression to identify risk factors. Results: MDR KP-BSI prevalence was 22.5% (54/240). The MDR KP-BSI group had higher rates of comorbidities (hemiplegia, COPD/severe asthma, chronic cardiac insufficiency, cerebrovascular accident) and higher disease severity scores (APACHE II, SOFA, Pitt bacteremia, Charlson index, all Conclusion: These predictors emphasize the need for antibiotic stewardship, infection control, and early interventions in high-risk patients to reduce MDR KP-BSI incidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.